The factors affecting local tumor control after stereotactic body radiotherapy for non-small cell lung cancer

Stereotactic body radiotherapy (SBRT), also called stereotactic ablative radiotherapy (SABR), has been widely used as an effective treatment for early-stage lung cancer, especially in medically inoperable cases (1,2). The local control (LC) rates after SBRT for early-stage non-small cell lung cancer (NSCLC) have been reported to be 85-98% (1). Although the treatment results seem to be favorable, several risk factors for local tumor progression have been reported. Here, we would like to summarize and discuss about reported factors that affect local tumor control after SBRT.